- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate with Dabrafenib with trametinib being a paediatric extension of TA544.
- ID number:
- 11839
Project Team
- Project lead
- Danielle Lees
Email enquiries
If you have any queries please email Topic.Selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 March 2026 | Topic prioritisation. Not selected |
| 04 February 2026 | Prioritisation board meeting |
| 06 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on how we select topics for development, please see our page about topic prioritisation